Bayer Reaffirms 2025 Outlook Following Robust First-Quarter Performance, Showcases Strength in Pharmaceuticals and Strategic Advancements in Crop Science Bayer AG has started 2025 with a strong operational footing, underscoring confidence in its full-year guidance amid an increasingly complex economic and…
AstraZeneca Unveils Expansive Respiratory Portfolio and Pioneering Clinical Data at ATS 2025 to Advance Care Across Asthma, COPD, and Inflammatory Lung Diseases AstraZeneca is poised to make a significant impact at the 2025 American Thoracic Society (ATS) International Conference in…
TVC Partners with Norbrook to Bring Felanorm™ to Independent Veterinary Practices The Veterinary Cooperative (TVC), the premier group purchasing organization dedicated to supporting independent veterinary practices across the United States, is proud to announce a groundbreaking partnership with Norbrook Animal…
Orca Bio Unveils New Leadership Team Changes Orca Bio, a late-stage biotechnology company dedicated to transforming the treatment landscape for patients through its cutting-edge high-precision cell therapies, has announced an important leadership transition. The company’s co-founder and Chief Scientific Officer…
Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile (almonertinib mesylate tablets) has received approval in China for a…
Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the IL-23 receptor. The study included adults and adolescents (12 years…
Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with Lilly committing up to $250 million over the next eight…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…
Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership agreement with Nagasaki University (Nagasaki City, Nagasaki), Saraya Co., Ltd.…
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in adults…
Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to deliver sustained, long-term growth and expand access to its medicines…
